NCT04388501

A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants

A Single-center, Open-label, Randomized, Three-way Cross-over Study Evaluating Drug Drug Interaction Between JNJ-70033093 and Atorvastatin in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Janssen Pharmaceutica N.V., Belgium · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the potential pharmacokinetics (PK) interaction between milvexian and atorvastatin (and its metabolites) in healthy participants at steady state.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Milvexian	Participants will receive milvexian capsules orally qd for 5 days as per the assigned treatment sequence.
DRUG	Atorvastatin	Participants will receive atorvastatin tablets orally qd for 5 days as per the assigned treatment sequence.

Timeline

• Start date: 2021-06-07
• Primary completion: 2021-10-25
• Completion: 2021-10-27
• First posted: 2020-05-14
• Last updated: 2025-03-30

Locations

1 site across 1 country: Belgium